ASCO 2015 Highlights

New Mexico Oncology Medical Home

Cancer Center Profile

October 2014, Vol 5 , No 8

Value-Based Cancer Care (VBCC) discussed these questions with Barbara L. McAneny, MD, CEO, New Mexico Oncology Hematology Consultants, who established the New Mexico Cancer Center’s Oncology Medical Home as part of the COME HOME award from the Center for Medicare and Medicaid Innovation.

Enzalutamide Long-Term Safety and Efficacy in Hormone-Naïve Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Maximal Androgen Depletion with Abiraterone Acetate Followed by Molecular-Targeted Therapies in Metastatic Prostate Cancer: Finding an Androgen-Signaling Signature to Predict Response

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Chemohormonal Therapy versus Hormonal Therapy Alone in Men with Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

AR-V7 Splice Variant as Prognostic Marker for Resistance to Enzalutamide or Abiraterone in Men with Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Nivolumab versus Investigator’s Choice of Chemotherapy in Patients with Advanced Melanoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Nivolumab Improves Survival in Ipilimumab-Naïve Patients with Advanced Melanoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Two Dosing Schedules of Pembrolizumab for Patients with Advanced Melanoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Updated OS Data for the CA184-043 Trial: Immunotherapy with Ipilimumab Does Not Improve Survival in Patients with Metastatic Prostate Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Afatinib Improves Outcomes in Patients with Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Page 214 of 330